🚨 Big news! 🚨 Our lab's latest paper by Jamil Nehme (@jamilnehme.bsky.social) is out now:
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer.
Check it out! (doi.org/10.1038/s443...) Congrats, Jamil! #CancerResearch #CDK46 #BreastCancer
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer.
Check it out! (doi.org/10.1038/s443...) Congrats, Jamil! #CancerResearch #CDK46 #BreastCancer
February 10, 2025 at 4:12 PM
🚨 Big news! 🚨 Our lab's latest paper by Jamil Nehme (@jamilnehme.bsky.social) is out now:
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer.
Check it out! (doi.org/10.1038/s443...) Congrats, Jamil! #CancerResearch #CDK46 #BreastCancer
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer.
Check it out! (doi.org/10.1038/s443...) Congrats, Jamil! #CancerResearch #CDK46 #BreastCancer
CDK4/6i resistance in HR+/HER2− BC
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance
December 5, 2025 at 8:15 AM
CDK4/6i resistance in HR+/HER2− BC
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance
💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making.
ja.ma/3ZAACFp
ja.ma/3ZAACFp
February 19, 2026 at 5:00 PM
💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making.
ja.ma/3ZAACFp
ja.ma/3ZAACFp
CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence.
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer - Marya Hussain, Christine Brezden-Masley, Stephen Chia, Giuseppe Curigliano, Marc Webster, Jan-Willem Henning, 2025
The introduction of the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib to the adjuvant setting marks a significant advancement ...
buff.ly
October 15, 2025 at 7:15 AM
CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence.
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
Check it out: buff.ly/Lpmp3f0
#oncology #breastcancer #cdk46
7-year data from monarchE and 5-year data from NATALEE confirm it: CDK4/6 inhibitors aren’t just delaying breast cancer recurrence; for some patients, they appear to be curing it. www.onclive.com/view/adjuvan... #BreastCancer #CDK46 #TCSC
Adjuvant CDK4/6 Inhibitors Gain Ground as Oral SERDs Emerge to Tackle Endocrine Resistance in Early HR+ Breast Cancer | OncLive
Erica L. Mayer, MD, MPH, discusses updated data with CDK4/6 inhibitors and ongoing investigations of oral SERDs in HR-positive breast cancer.
www.onclive.com
April 27, 2026 at 8:00 AM
7-year data from monarchE and 5-year data from NATALEE confirm it: CDK4/6 inhibitors aren’t just delaying breast cancer recurrence; for some patients, they appear to be curing it. www.onclive.com/view/adjuvan... #BreastCancer #CDK46 #TCSC
CDK4/6 Inhibition Refined in HR+ Breast Cancer, as Novel Combos Emerge https://www.onclive.com/web-exclusives/cdk46-inhibition-refined-in-hr-breast-cancer-as-novel-combos-emerge via @onclive
CDK4/6 Inhibition Refined in HR+ Breast Cancer, as Novel ...
Sara Hurvitz, MD, shares insight on the 3 CDK4/6 inhibito...
www.onclive.com
November 18, 2024 at 11:52 PM
CDK4/6 Inhibition Refined in HR+ Breast Cancer, as Novel Combos Emerge https://www.onclive.com/web-exclusives/cdk46-inhibition-refined-in-hr-breast-cancer-as-novel-combos-emerge via @onclive
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 https://www.infosalut.com/investigacio/estudis-i-projectes/17267
https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
April 11, 2025 at 9:44 AM
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 https://www.infosalut.com/investigacio/estudis-i-projectes/17267
https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making.
ja.ma/4dZWna1
ja.ma/4dZWna1
April 24, 2026 at 11:00 AM
💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making.
ja.ma/4dZWna1
ja.ma/4dZWna1
CDK4/6 inhibitors and the Kidney http://www.nephronpower.com/2021/12/topic-discussion-cdk46-inhibitors-and.html #nephronpower
Topic Discussion: CDK4/6 inhibitors and the Kidney
Selective estrogen receptor inhibitors and aromatase inhi...
www.nephronpower.com
December 11, 2024 at 12:21 AM
CDK4/6 inhibitors and the Kidney http://www.nephronpower.com/2021/12/topic-discussion-cdk46-inhibitors-and.html #nephronpower
乳癌用藥健保給付限時成窘境 病友協會盼改善 | 生活 | 中央社 CNA
www.cna.com.tw
May 7, 2025 at 6:36 AM
The combination of giredestrant + palbociclib produced a numerical PFS improvement in patients with ER-positive/HER2-negative advanced breast cancer. 📊🧬
Read more ➡️ www.onclive.com/view/giredes...
#ASCO26 #BreastCancer #HRPositiveBreastCancer #ERPositive #CDK46 #Oncology #bcsm
Read more ➡️ www.onclive.com/view/giredes...
#ASCO26 #BreastCancer #HRPositiveBreastCancer #ERPositive #CDK46 #Oncology #bcsm
Giredestrant Plus Palbociclib Yields Numerical PFS Benefit in ER+, HER2– Advanced Breast Cancer | OncLive
Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.
www.onclive.com
June 2, 2026 at 10:17 PM
The combination of giredestrant + palbociclib produced a numerical PFS improvement in patients with ER-positive/HER2-negative advanced breast cancer. 📊🧬
Read more ➡️ www.onclive.com/view/giredes...
#ASCO26 #BreastCancer #HRPositiveBreastCancer #ERPositive #CDK46 #Oncology #bcsm
Read more ➡️ www.onclive.com/view/giredes...
#ASCO26 #BreastCancer #HRPositiveBreastCancer #ERPositive #CDK46 #Oncology #bcsm
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudio donde se analizan las comorbilidades en cáncer de mama metastático HR+/HER2- con CDK4/6 https://www.infosalut.com/es/17267 https://doi.org/10.1016/j.clbc.2024.12.016
#cáncerdemama #cáncerdemamametastático #HER2 #CDK46
#cáncerdemama #cáncerdemamametastático #HER2 #CDK46
April 4, 2025 at 4:01 PM
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudio donde se analizan las comorbilidades en cáncer de mama metastático HR+/HER2- con CDK4/6 https://www.infosalut.com/es/17267 https://doi.org/10.1016/j.clbc.2024.12.016
#cáncerdemama #cáncerdemamametastático #HER2 #CDK46
#cáncerdemama #cáncerdemamametastático #HER2 #CDK46
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 https://www.infosalut.com/investigacio/estudis-i-projectes/17267 https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
April 4, 2025 at 9:01 AM
#PublicaSalutIB 💉👩 Son Llatzer participa en un estudi on s'analitzen les comorbiditats en càncer de mama metastàtic HR+/HER2- amb CDK4/6 https://www.infosalut.com/investigacio/estudis-i-projectes/17267 https://doi.org/10.1016/j.clbc.2024.12.016
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
#càncerdemama #càncerdemamametastàtic #HER2 #CDK46
#転移乳がん #CDK4/6阻害薬 #全生存期間 #乳がん治療
【ブログ更新】
転移乳がん治療の新たな視点：CDK4/6阻害薬、使用タイミングで全生存期間に差なし？最新メタ解析が示す未来 https://kenko-mosunon.blogspot.com/2025/08/cdk46.html
【ブログ更新】
転移乳がん治療の新たな視点：CDK4/6阻害薬、使用タイミングで全生存期間に差なし？最新メタ解析が示す未来 https://kenko-mosunon.blogspot.com/2025/08/cdk46.html
August 24, 2025 at 9:05 PM
#転移乳がん #CDK4/6阻害薬 #全生存期間 #乳がん治療
【ブログ更新】
転移乳がん治療の新たな視点：CDK4/6阻害薬、使用タイミングで全生存期間に差なし？最新メタ解析が示す未来 https://kenko-mosunon.blogspot.com/2025/08/cdk46.html
【ブログ更新】
転移乳がん治療の新たな視点：CDK4/6阻害薬、使用タイミングで全生存期間に差なし？最新メタ解析が示す未来 https://kenko-mosunon.blogspot.com/2025/08/cdk46.html